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1  introDuction
Sequencing of the human genome was completed, ahead of schedule, in spring 
2003. This, and subsequent developments, have lead to considerable advances 
in our understanding of the influence of genomic variation on human diversity 
and susceptibility to disease, and promise great opportunities for the prediction, 
treatment and prevention of common, complex diseases.1 Many challenges remain, 
with one of the most significant being how to develop strategies for incorporating 
genetic susceptibility testing (or genomic profiling) into clinical practice.2 
There is a lack of consensus regarding the likelihood of this development, and the 
expected timeframe if it does eventuate. Some claim that the rewards of the human 
genome project will include ‘a new understanding of the genetic contribution 
to human disease and the development of rational strategies for minimizing or 
preventing disease phenotypes altogether’.3 Others are more cautious, suggesting 
that decades of epidemiological study and clinical evaluation of interventions will be 
required.4 Some are sceptical that genomics will ever revolutionise the way in which 
common diseases are identified or prevented with their doubts stemming from issues 
such as incomplete penetrance of genotypes for common diseases, the limited ability 
to tailor treatment to genotypes and the low magnitude of risks conferred by various 
genotypes for the population at large.5,6 
We cannot be certain how useful genomics will prove to be in the clinical setting; 
but we can say that there are obvious advantages to using a pre-existing screening 
infrastructure if susceptibility testing is to be implemented at a population level. This 
point has not gone unrecognised, with one suggestion that has attracted attention 
being to utilise samples taken for existing newborn screening programmes for 
genomic profiling.7,8 Such reports also draw attention to an issue of considerable 
importance: we know very little about the potential psychological impact of testing 
for these individual genetic differences, particularly in the newborn period. In other 
words how does this type of genetic information affect a parent’s perceptions of 
their child? Until there is more research and debate regarding these issues we cannot 
adequately assess whether the benefits of testing are likely to outweigh the risks and, 
without this knowledge, it would be premature to consider clinical application.
This report aims first to describe what is meant by susceptibility testing and explain 
how it differs from testing for monogenic disorders. It will then focus on more 
detailed discussion of type 1 diabetes (T1D) as this provides a useful disease model 
for this type of screening. Subsequent discussion will detail some of the challenges 
that must be addressed before clinical application of susceptibility testing can be 
considered. This will include reference to practical and scientific issues but will focus 
more on emerging ethical and social considerations and, in particular, will discuss 
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the potential for harmful effects upon children and families that may arise from a 
combination of factors related to the tests and features of the newborn period. 
2  the nature oF genetic suscePtiBility tests
The following definitions are helpful. Genetic susceptibility testing: ‘Testing for DNA 
sequence variation (SNPs) associated with increased or decreased risk of disease’.
Genomic profiling: ‘Concurrent detection of multiple gene variants (SNPs) that 
have been associated with greater risk or predisposition to a particular disease or 
condition’.4 
About 99.8 per cent of human DNA sequences are identical across the population. 
Genomic profiling focuses on the 0.2 per cent that is variable. These variations are 
termed single-nucleotide polymorphisms (SNPs) and refer to single-nucleotide or 
single-letter spelling differences between the DNA of different individuals. SNPs are 
thought to make up about 90 per cent of all human genetic variation and occur 
at every one hundred to three hundred bases along the three-billion-base human 
genome. This means that the human genome has about ten million polymorphisms, 
which are defined as genetic variants in which the minor gene forms occur at least 
once out of every one hundred forms. Any two unrelated humans will have millions 
of genetic differences that contribute to the fact that they look and behave differently 
from one another.9 These variations may predispose or protect individuals from 
developing various disorders, such as T1D, and affect how people respond to disease 
and environmental exposures such as bacteria, viruses, toxins and chemicals, and 
drugs and other therapies. They also contribute to biological variation such as height 
and metabolism, and some are thought to have no effect.10 
The conditions in which SNPs play important roles are non-mendelian diseases, 
also called multifactorial, complex or common diseases, that are the main cause of 
morbidity and mortality in developed countries. Multifactorial diseases, for example, 
such as T1D, obesity, cardiovascular disease and asthma, each have a population 
frequency greater than 1 per cent. The difficulty is that, although gene variants 
predispose individuals to common diseases, they do not cause disease in isolation, 
rather operating in a highly complex manner, in combination with other gene 
variants and with the environment.9 So, whereas a positive newborn screening test 
for phenylketonuria (PKU) means that the biochemical disorder is already present 
and the disease will develop rapidly without treatment, a positive susceptibility test 
gives an individual information about the risk of developing a disease some time in 
the future. The increased risk conferred by an individual gene variant is usually in the 
region of two (twice the average risk), and almost always less than twenty.11 This type 
of information is derived from population genetic studies and is usually presented 
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in terms of a probability estimate or odds ratio; so for individuals considerable 
uncertainty remains as to whether they will develop the condition and, if so, when.12 
  tyPe 1 DiaBetes (t1D) as a Disease moDel 
A useful model on which to base discussions concerning the potential use of genetic 
susceptibility testing in clinical practice is provided by T1D. It is one of the most 
common chronic childhood diseases, with a rising incidence (3 to 4 per cent per year 
in most developed countries), particularly in the under four age group.13,14 At present, 
development of the disease necessitates life-long adherence to a difficult therapeutic 
regime that is only partially effective in preventing acute and chronic complications.15 
These facts, as well as the existence of a long period of latent autoimmunity preceding 
the onset of clinical diabetes, make the possibility of disease prevention an attractive 
and potentially achievable goal.16 
.1  aetiology of t1D
T1D is representative of the type of condition that may be screened for use of genetic 
susceptibility testing, in that it is a multifactorial condition with disease development 
dependent upon an undetermined number of genetic and environmental 
factors.17 The chief genetic determinant of susceptibility to diabetes, contributing 
approximately 50 per cent of the genetic risk, lies within the class II region of the 
major histocompatibility complex on chromosome 6.18 More than 90 per cent of 
patients who develop T1D have either the DR3 and/or DR4 allele of the HLA-DRB1 
gene, whereas fewer than 40 per cent of healthy controls have these alleles. Depending 
on the population, people homozygous for the high-risk DR4 allele have a ten to 
fifteen-fold increased risk of T1D, and people heterozygous for the DR3/DR4 alleles a 
twenty to thirty-fold increased risk.19 Of the HLA-DRB1 *04 subtypes, *0401, *0402, 
*0404 and *0405 confer the highest relative risk of T1D, whereas *0403, *0406 and 
*0408 confer protection against T1D.19 
This concentration of the genetic risk makes general population screening for higher 
risk individuals a possibility. Population screening for genetic susceptibility to T1D 
does not currently form part of current clinical practice but is the object of several 
longitudinal prospective studies20–23 and, more recently, a larger prospective study (The 
Environmental Determinants of Diabetes in the Young (TEDDY) study) involving a 
consortium of 6 centres in the United States, Scandinavia and Europe.24 The long-
term goal of the TEDDY study is the identification of infectious agents, dietary 
factors or other environmental agents that trigger beta cell autoimmunity, T1D, or 
both in genetically susceptible individuals or which protect against the disease. It is 
hoped that identification of such factors will lead to a better understanding of disease 
pathogenesis and will ultimately result in new strategies to prevent, delay or reverse 
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T1D.24 T1D is one of the first of many diseases with complex genetic and environmental 
determinants that is being studied in this manner, but the characterisation of at-risk 
groups by genotype with the view to instituting preventative measures could equally 
apply to other common multifactorial conditions, such as asthma and obesity.
  challenges to incorPorating t1D testing into    
 newBorn screening
Large prospective studies such as those investigating the pathogenesis of T1D 
provide us with much information and many opportunities concerning the use of 
susceptibility testing in the newborn period. The remainder of this report will discuss 
some of the challenges that need to be addressed before it will be possible to translate 
advances in the field of genomic medicine into health benefits. I will refer specifically 
to information that can be derived from prospective T1D studies to illustrate various 
points, and will highlight opportunities to gather more empirical evidence. 
The challenges are numerous and also varied, spanning scientific and practical, as 
well as ethical, legal and social, issues. In practice these areas are closely intertwined, 
and difficult to discuss in isolation; however, for the sake of clarity, I will consider 
them separately here. Scientific and practical issues are not the main focus of this 
discussion and will be covered only briefly, with reference to work by those who 
have discussed these issues in considerable depth. This will leave greater scope for 
discussing ethical and social issues and, in particular, articulating more fully those 
issues that are specific to testing in the newborn period. 
.1  scientific and practical issues
All medical tests vary with regard to how well they are able to predict a particular 
outcome, and genetic susceptibility tests are no different in this respect. The need 
for evaluation of genetic tests in population-based settings, before they can be used 
in clinical practice, has been recognised for some time.2,25,26 An approach must be 
developed that can help to determine the potential value of the test in patient care. 
This approach is called ACCE (analytic validity; clinical validity; clinical utility; and 
ethical, legal and social implications).27 The system is well developed and consists of 
forty-four targeted questions intended to determine what is currently known about 
the test and disorder in question, as well as to identify gaps in current knowledge.2
‘Analytic validity’ refers to the accuracy of the test in identifying the genotype of 
interest. This encompasses analytic sensitivity and specificity as well as issues relating 
to laboratory quality control.28 ‘Clinical validity’ refers to the accuracy and reliability 
with which a test detects or predicts a particular clinical outcome and includes the 
detection and false positive rates as well as penetrance.28 All of these factors can be 
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affected by the setting in which the test is performed (e.g. population screening versus 
clinical diagnosis) and the frequency of the mutation in the population.2 ‘Clinical 
utility’ refers to the usefulness of the test and the value of the information to the person 
being tested.29 Measuring clinical utility can be difficult, as it requires evaluation of 
the risks and benefits of testing. This may include knowledge of the natural history 
of the disorder; availability, uptake and effectiveness of interventions; impact of 
interventions on health outcomes; cost-effectiveness; and social acceptability.2 
For most genetic susceptibility tests there are currently significant gaps in our 
knowledge concerning analytic validity, clinical validity and utility, or the tests do not 
rate well enough in these areas to be considered for clinical use. In the case of T1D, for 
example, a HuGENet review concerning the HLA-DQ locus noted the relatively low 
sensitivity and specificity estimates of high-risk alleles in the general population and 
the current lack of an effective preventive intervention. It also articulated the need 
for more information concerning population-based, risk factor-specific incidence 
rates in all ethnic groups, as well as the need to consider genetic counselling services 
and genetic education for T1D families and health professionals.30 
Some authors have suggested that genetic testing for common diseases will not be 
useful in practice because of these issues and, in particular, because of the incomplete 
penetrance and low magnitude of risks associated with various genotypes in the 
population.5, 31 While this argument may be a useful counter-balance to some of the 
hype associated with genetic susceptibility testing, it probably overstates the intrinsic 
limitations. This is because it considers testing for only a single genetic factor, whereas 
simultaneous testing of multiple predisposing alleles is likely to become the standard 
for multifactorial diseases.32
In order to obtain good information about analytic and clinical validity and utility, 
ongoing high quality (and expensive) biomedical research will be required; a clear vision 
for the way in which this research should progress has already been developed.33 This 
seminal paper provides ‘an overview of the broad landscape of scientific opportunity’ 
and suggests a varied range of scientific endeavours. These include collection of large-
scale genomic data sets such as the HAPMAP project34 and longitudinal population 
cohort studies designed to identify genetic and environmental contributors to health 
and assess the effect of individual gene variants on disease risk.33
.2  ethical and social issues
There may be ethical and social concerns related to testing people of any age for 
genetic susceptibility to disease. These include: 
• Issues related to informed consent for those undergoing testing. While important 
for all undergoing testing this issue is particularly pertinent to the testing of 
young children and is discussed in detail in the report by Deborah Lawson
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• Issues related to privacy, storage and access, discussed in the report ‘Newborn 
Screening and Related Legal Issues’ by Kirsty Dobbs and Richman Wee
• The potential for stigmatisation and discrimination, including by employers and 
insurance agencies. Discrimination is discussed in relation to race and genetics 
in the final report of this series
• Potentially adverse effects of testing, including physical and psychosocial harms. 
The last of these issues, namely the potentially adverse effects of testing, have not been 
addressed in detail elsewhere in this series of reports and there is a general paucity of 
data existing in the literature, particularly in relation to the testing of children. This is 
especially true when considering adverse psychosocial reactions, despite the fact that 
there are several reasons for giving these issues additional consideration when testing 
is performed in the newborn period. 
  concerns relateD to testing in the newBorn PerioD
There are several reasons for being particularly aware of the potential for adverse 
psychosocial effects of genetic susceptibility testing in the newborn period. These 
include:
• Specific features of the newborn period
• Existing evidence concerning psychosocial consequences of other newborn 
screening programmes
• The nature of genetic susceptibility tests
• Guidelines on predictive genetic testing in childhood.
.1  specific features of the newborn period
The newborn period has long been recognised as a time when both babies and their 
parents are vulnerable. In particular we know that the first few months of life represent 
a critical phase of infant–parent bonding. For example, in one report mothers who 
were separated from their newborn babies because of prematurity reported higher 
levels of preoccupation with thoughts of infant safety and well-being than mothers 
of term babies, and attachment behaviours declined linearly with the duration of 
mother–infant separation.35 It is thought that early interruption of the bonding 
process can have lasting effects on the parent–child relationship.
In addition to the issue of bonding it is also known that external influences, 
including the psychological or emotional state of the parents, can have a profound 
and permanent effect on a child’s physical36 and psychological development.37 This 
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has been most clearly demonstrated in situations of abuse or neglect38 but also holds 
true for less extreme situations. 
These two important psycho-developmental issues merit specific consideration when 
assessing proposals for newborn genetic susceptibility screening programmes.
 
.2  existing evidence concerning psychosocial effects of newborn screening 
The fact that psychosocial issues may be important has long been recognised in 
relation to previous and existing newborn screening programmes. Even current well-
accepted tests are not devoid of adverse psychosocial reactions. For instance one study 
has shown that some parents who received false positive results from newborn PKU 
testing continued to believe that their child may be developmentally delayed despite 
subsequent normal test results.39 Similarly, families who received false positive results 
for hypothyroidism reported greater strains on marriage and difficulties in their 
relationships with their children.40 There has been general agreement however that 
the magnitude of benefit (potential avoidance of profound intellectual impairment 
or death) from these programmes outweighs these potential harms. 
There are also several examples of newborn genetic screening worth considering. 
First, in Sweden in the early 1970s a programme screening for alpha 1 antitrypsin 
deficiency was commenced.41 This autosomal recessive disorder can lead to liver 
disease in infancy and chronic lung disease in young adulthood. However, penetrance 
and expressivity are variable, meaning that who will be affected and to what degree 
is uncertain. Parents of children at risk were advised that cigarette smoking could 
hasten or worsen their child’s lung disease. 
The screening programme was discontinued after five years because of the 
psychological stress it had caused some families whose child had tested positive.42 
Later data found that there was actually increased cigarette smoking among fathers 
of affected children and negative long-term effects upon the mothers’ mental health 
and mother–child interactions.41,42 Data regarding this programme should be treated 
with some caution as information provision and counselling services in the 1970s 
may not be analogous to those employed today. However, the results do merit 
consideration as the tests have some features, such as uncertainty as to who will 
develop the disease and if so when, in common with the type of susceptibility tests 
that could be employed today.
There is also some data available concerning newborn screening for cystic fibrosis 
(CF). Testing for this disorder is a component of many current newborn-screening 
programmes, including the New Zealand programme. One study, comparing the 
strength of overprotective child-rearing attitudes of twenty-nine mothers whose 
children were screened for CF (thirteen had symptomatic children and sixteen 
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asymptomatic children) with the attitudes of twenty-nine mothers whose children 
were diagnosed after the onset of symptoms, indicated that newborn screening had 
not increased, and in some cases had decreased, a mother’s tendency to overprotect 
her child with CF. The authors also noted that delays in diagnosis when screening was 
not conducted usually caused mothers considerable personal distress.43 The reduction 
in diagnostic delay is generally considered to be one of the major psychosocial 
advantages of newborn screening for CF.44,45 
However, another study describing parents’ attitudes toward newborn screening for 
CF revealed that a minority of mothers reported experiencing difficulties with infant 
bonding in relation to the screening process. Some of these mothers acknowledged 
temporary rejection of their babies during the period of uncertainty between initial 
positive immunoreactive trypsinogen (IRT) screen and substantive diagnosis.46 A 
more recent study has also highlighted the emotional distress parents experience 
during this period of diagnostic uncertainty.47 This small amount of data concerning 
the detrimental effects of ‘uncertainty’ in relation to newborn testing is potentially 
highly relevant to discussion of genetic susceptibility testing for conditions like T1D. 
A further issue is that CF screening programmes may also lead to identification of 
healthy carrier children, which can lead to anxiety and misunderstanding.44 The 
evidence concerning psychosocial reaction to screening for CF is therefore slightly 
conflicting; but, again, on balance many have concluded that the benefits (such as 
improved nutritional outcomes) outweigh these harms.44 
Finally, in some areas screening for Duchenne muscular dystrophy (DMD) has been 
introduced. DMD is a lethal genetic disease transmitted to boys by healthy women 
who carry the defective gene on one of their two X chromosomes. Affected boys are 
healthy at birth, show early signs of muscle weakness by age three to four years, become 
wheelchair-bound by eleven to twelve years and usually die in their late teens to early 
twenties.48 Reports from Wales have found no negative effect of this type of newborn 
screening on the early mother–baby relationship. In particular there was no evidence 
of either rejection or overprotection of infants diagnosed pre-symptomatically 
through screening during the first year of life.49 It therefore seems that parents may 
prefer early diagnosis through screening, even for untreatable diseases such as DMD, 
with the declared advantage being that they can prepare themselves emotionally and 
practically and consider their reproductive options.49,50 
In summary, there is a wide awareness of the potential for adverse psychosocial effects 
in relation to current newborn screening programmes. In organising programmes, 
attempts have been made to minimise the potential for these adverse reactions (for 
instance, by ensuring very low rates of false positive results) but it is accepted that, in 
some cases, they cannot be entirely eliminated. Current programmes are justified on 
the basis that the benefits of testing outweigh the potential for harm. 
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.  the nature of genetic susceptibility tests
SNPs or gene variants predispose individuals to common diseases but do not cause 
disease in isolation, rather operating in a highly complex manner, in combination 
with other gene variants and with the environment.9 As already discussed this means 
individuals are still left with considerable uncertainty as to whether they will develop 
the condition and, if so, when.12 As well as this intrinsic uncertainty, the way in 
which the risk is interpreted by individuals is also likely to be extremely variable and 
dependent upon a range of personal characteristics and experiences.51 Evidence from 
current screening programmes for CF (discussed earlier) suggests that parents have 
difficulty dealing with brief periods of diagnostic uncertainty. It is not yet known 
how parents will react to the more prolonged uncertainty associated with genetic 
susceptibility to common diseases. 
.  guidelines on predictive genetic testing in childhood
The Human Genetics Society of Australasia (HGSA) policy on predictive testing 
in children and adolescents states that ‘children should only have pre-symptomatic 
and predictive testing when the resulting information will be used to help with their 
health management in the immediate future’.52 Similar policies exist in most other 
developed countries.53,54 The reasoning behind this prohibitive stance relates not only 
to an attempt to protect the evolving autonomy of the child, but also to concerns 
about the psychosocial sequelae that genetic testing in childhood may generate. 
In particular there is concern that when testing occurs in the newborn period the 
parents’ psychological reaction may have a direct and permanent effect upon the 
child. There is further discussion on guidelines in the section of Deborah Lawson’s 
report entitled ‘Setting the Scene: Genetic Testing Context in New Zealand – New 
Issues, Professional Guidelines, Attitudes and Practice’.
In summary, there is an awareness of the potential for adverse parental psychosocial 
reactions to existing newborn screening programmes, and of the fact that the newborn 
period is a particularly important period in terms of bonding and child development. 
For these, and other, reasons there is expert consensus against predictive genetic 
testing of newborns where there is no clear therapeutic benefit. Genetic susceptibility 
testing in the newborn period remains particularly controversial largely because of 
the significant potential imbalance between benefits and psychosocial risks for the 
child.55 The following section reflects current knowledge concerning the risk and 
benefits of testing newborns for genetic susceptibility to T1D and highlights areas 
where more empirical evidence is required.
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  Potential BeneFits anD harms oF newBorn genetic   
 testing For suscePtiBility to t1D
At present, relatively good predictions of type 1 diabetes can be obtained by genotyping 
and measuring auto-antibodies, but no preventative measure is available. However, 
children at increased genetic risk enrolled in longitudinal studies do show improved 
health status at the onset of type 1 diabetes compared to children not involved in these 
studies.15, 56 This is presumably related to medical surveillance and the heightened 
awareness of parents. Further research in this area aims to reveal more details of the 
pathogenesis of the disease and eventually lead to some form of prevention. At this 
level of benefit, screening entire populations of newborns for genetic susceptibility 
to type 1 diabetes would become significantly more attractive. There is therefore a 
pressing need to articulate more clearly the potential harmful effects of newborn 
susceptibility testing and to research areas where empirical evidence is lacking. The 
next section of this report aims to address these issues with particular reference to 
type 1 diabetes.
.1  Potential harmful physical effects 
Collection of the blood sample required for genetic analysis can be performed entirely 
painlessly (cord blood sample) or with minimal discomfort (heel-prick sample). 
However there are other potential physical discomforts associated with this type of 
testing. First, if children test positive for a particular susceptibility gene they will 
require some sort of immunological surveillance throughout childhood. Under study 
protocols, such as TEDDY, children who test positive for susceptibility alleles for T1D 
require blood tests every three to six months for auto-antibody screening. Later, some 
children may be enrolled in prevention trials. The potential harms associated with 
surveillance or preventative measures are largely predictable and must be carefully 
assessed in trials prior to any proposed clinical introduction of newborn genomic 
profiling. This is an important component of the clinical utility of the test. 
Other physical harms may be less predictable, and more dependent on the reaction 
of individual parents to their child’s test result. For example, a recent study of 
mothers of children at genetic risk for T1D has shown that many of them alter the 
way they treat their child despite there being no current medical recommendation 
to do this. This included monitoring behaviours (e.g. checking blood glucose) and, 
in some cases, modifying the child’s diet and limiting physical activity.57 In the 
absence of definitive preventative measures the potential for harm may be increased 
if the natural parental urge to protect one’s child drives a search for preventative 
or therapeutic strategies. For example, some parents in T1D studies are known 
to have altered their child’s milk consumption, from standard cow’s milk to milk 
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containing a different protein, because of largely unsubstantiated claims that the 
former triggers diabetes whereas the latter does not.12 While this strategy is unlikely 
to be harmful, other similar interventions may not be so innocuous, particularly 
when one considers the permanent neuro-developmental changes that may occur in 
relation to environmental influences in early childhood. In the case of susceptibility 
testing these negative effects may accrue in large numbers of children who were 
never destined to develop the condition to which they are ‘susceptible’. One might 
argue that these reactions could be remediated by educative measures but this would 
require considerable resource allocation, and may still be only partially effective. 
Even with optimal counselling services concepts of risk are difficult to convey, and 
reactions depend upon a complex interplay of individual characteristics.58 This is an 
important area for future research and strategies to address these issues should be 
incorporated into prospective cohort studies wherever possible. 
Finally, it is not only the children who test positive for an increased risk genotype 
who are at risk of potential harm through susceptibility testing. Having a low 
risk genotype for a multifactorial disease does not eliminate the possibility of the 
condition developing. For the susceptibility tests currently used to screen for T1D it 
simply means that the risk is low (less than 1 in 1500). It is imperative that parents 
of these children are not falsely reassured and would still recognise the symptoms of 
developing illness were they to occur. 
.2  Potential harmful psychosocial effects 
I have previously highlighted two important aspects of the newborn period that 
may be relevant to discussions about the potential harmful effects of newborn 
genetic susceptibility testing. These are that the first few months of life represent 
a critical phase of infant–parent bonding and that external influences, including 
the psychological or emotional state of the parents, can have a profound and 
permanent effect on child development.37 There are several ways that receiving 
information about a child’s genetic risk of developing T1D could affect parents and 
impact upon the child. Some of these will be reviewed in the following section of 
the report. 
6.2.1  Parental psychological disturbance
First, parents may become significantly distressed by the knowledge that their child 
is at risk of T1D. This would be an unfortunate occurrence in its own right but could 
also alter the parent–child bonding process and the parents’ ability to care for and 
nurture their child. Empirical evidence concerning parental reaction to newborn 
susceptibility testing is gradually accruing, particularly in relation to newborn T1D 
screening. It appears that in fact very few parents are significantly distressed by this 
type of genetic knowledge. For example, Bennett Johnson et al. in Florida studied 435 
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mothers of infants with increased genetic risk of T1D at four months and one year 
post risk notification and found that, for most mothers, this type of newborn genetic 
screening was not associated with significantly elevated maternal anxiety, and that 
anxiety further dissipated over time. Some mothers (for example Hispanic mothers 
and those with infants sub-classified as extremely high risk) did experience more 
anxiety than pregnant or working women comparison groups and this merits further 
investigation.59,60 Yu et al. in Colorado studied twenty-three mothers of infants at high 
genetic risk of T1D, and sixty-five mothers of low-risk infants, using the parenting 
stress index (PSI) at baseline (five to seven weeks postpartum) and four to five months 
after risk notification. They did not find a statistically significant association between 
infant genetic risk status and change in maternal scores on the PSI.61 
My own research in this area, undertaken at the University of Otago in Dunedin, 
New Zealand, involved studying three mother–baby cohorts: thirty-eight infants 
at increased genetic risk of T1D, seventy-three at low genetic risk and seventy-six 
who had not undergone testing. The Edinburgh postnatal depression scale (EPDS) 
and State subscale, the State trait anxiety inventory (STAI), were administered at 
nine weeks, four months and one year postnatal age, with genetic risk notification 
occurring at ten weeks postnatal age. Statistical analyses were conducted to test for 
differences in questionnaire scores among the three groups. No difference among 
the groups was detected in EPDS score using linear mixed-effects model analysis. 
Maternal anxiety was paradoxically slightly lower in the increased-risk group shortly 
after notification of results (P=0.04) but there were no significant differences in the 
groups by one year. 62 These results concur with other investigators’ conclusions that 
informing parents that their baby is at genetic risk of T1D does not lead to clinically 
significant psychosocial disturbance as measured on standard rating scales.
Despite this reassuring data, when asked to rate their own degree of concern about 
their baby’s genetic risk, mothers of babies at increased risk reported significantly 
higher levels of concern than mothers of babies with low or unknown genetic risk.62 
Of course, this is not a surprising result: it seems unrealistic to think there will be 
no difference in psychosocial reaction between mothers of genetically susceptible 
babies and those of low-risk babies. In fact, one of the aims of any newborn screening 
programme involving genetic susceptibility testing must be to create some degree of 
heightened awareness for parents of the child’s health risks so that they participate 
in surveillance and preventative measures. It would clearly be wrong to overburden 
parents and create problems akin to the vulnerable child syndrome; just how 
much parental concern should we aim to generate? Determining precisely what an 
appropriate or acceptable parental response constitutes, and how best to achieve this 
in practice, is a challenge for the future. 
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6.2.2  Parental psychological preparation
Newborn screening for genetic susceptibility to multifactorial disorders differs 
from screening for DMD or CF, as it cannot provide the ‘benefit of certainty’ that 
is associated with tests for monogenic disease.53 Rather it highlights a specific level 
of uncertainty: parents must learn to live with the knowledge that their child might 
develop a condition, of uncertain clinical severity, at some point during childhood. 
Possessing knowledge that a child might develop a disease such as T1D at some stage 
in the future can be viewed in competing ways. Some parents may find this knowledge 
burdensome, particularly if no preventative measure is available or if there is a long 
time lag between the test and the potential intervention. The reported difficulties of 
parents dealing with much briefer periods of uncertainty in relation to cystic fibrosis 
screening47 may be relevant to this situation; how parents cope with more prolonged 
uncertainty requires further investigation. 
Other parents may feel empowered by the knowledge and their opportunity to detect 
potential problems early and potentially minimise morbidity. However, it must be 
remembered that any physical, emotional or practical preparation that parents make 
on the basis of genetic risk information from susceptibility tests may be pointless if 
the child never develops the condition (T1D, for example) as the majority of children 
with increased risk genotypes will not. 
It is important that parental reaction to the ongoing uncertainty associated with 
susceptibility to common diseases is monitored. There is not yet sufficient data 
available to make predictions about how different families will manage this type of 
information. However, it is likely that there will be a range of responses and that the 
need for counselling and support will vary. 
6.2.3  Parental perceptions of the child
A parent’s belief that their child is in some way vulnerable, or particularly susceptible 
to illness, can potentially have adverse effects upon the child’s development.63 This 
was first termed ‘vulnerable child syndrome’ by Green and Solnit in 1964, when 
reporting on a cohort of families whose children had suffered life-threatening 
illnesses in infancy and then completely recovered.64 The authors observed that 
the parents, particularly the mothers, continued to be anxious about their child’s 
health, and feared the child may die. It appeared that the parents’ perception of their 
child as being uniquely vulnerable led to difficulties in parent–child interaction. In 
particular, the parents overprotected the child, were unable to set age-appropriate 
limits and displayed excessive concerns about their child’s health in medical settings. 
The children, apparently responding to their parents’ expectations of vulnerability, 
showed exaggerated separation anxiety, sleep disorders, discipline problems, under-
achievement at school and distorted perceptions of their own health.64 
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Since the original description, aspects of the vulnerable child syndrome have been 
described in relation to many other conditions and disorders, such as false positive 
tests for PKU39 and innocent heart murmurs.65 More recently, a study has suggested 
that higher parental perception of child vulnerability is correlated with a worse 
developmental outcome in premature infants at one-year adjusted age.66 Although 
not all these families displayed the florid behavioural problems described in Green 
and Solnit’s original report, these studies provide evidence that heightened parental 
perceptions of a child’s vulnerability may contribute to long-term developmental 
problems.
The fact that genetic risk information may lead parents to perceive their child as being 
unwell, when actually they only have an increased risk of being ill in the future, is 
therefore of some importance and requires specific investigation. This is particularly 
true in the newborn period because of the unique vulnerability of this time. My 
own research, discussed in part earlier, has investigated this particular issue. In order 
to assess parental perceptions of their child we developed a ten-item self-report 
scale called the vulnerable baby scale (VBS).67 The VBS was based on an existing 
child vulnerability scale suitable for use with mothers of four to eight-year-old 
children,63 with modifications to make it developmentally appropriate for use with 
mothers of young babies. The scale aims to assess different aspects of perceptions 
of vulnerability including the degree of parental protectiveness; experience of 
separation anxiety; concern about the child’s health; and use of medical services. 
This scale was administered to the three mother–baby cohorts along with the anxiety 
and depression measures at nine weeks, four months and one year postnatal age. 
Statistical analyses showed no difference in VBS scores between the three groups, 
suggesting that the vulnerable child syndrome is unlikely to occur in relation to 
genetic risk status for T1D. 62
This section has highlighted the potential for psychosocial harm when genetic 
susceptibility testing is performed in the newborn period. For the most part, the 
small amount of empirical data concerning these risks suggests that in fact clinically 
significant disturbance is unlikely to occur. However, the research remains fairly 
limited both in scope and duration and further investigation will be required to 
elucidate more fully parental reaction to such testing and also to incorporate the 
responses of children as they reach an age where they can articulate their opinions. 
In advocating further research in this area, whether it is aimed at unravelling the 
pathogenesis of the disorder or determining psychosocial reaction to testing, it is 
important to consider whether the studies themselves are in fact ethically appropriate, 
given the general prohibitive stance concerning predictive genetic testing in children. 
If it is felt that the research is justifiable then future studies must be designed to 
minimise risks to children. 
11
7  genetic suscePtiBility research with chilDren
Views regarding the inclusion of children in research have evolved over time. When 
the Nuremburg Code was adopted in 1947 health research with children was subject 
to significant limitations in the Western world. Some years later the Declaration of 
Helsinki (1964) stated that research involving children must have potential diagnostic 
and therapeutic value for the participant; but later revisions of this document 
recognised the fact that research is necessary to promote the health of the population 
represented. By attempting to protect children from the risks associated with 
research they were also being excluded from the benefits. It is now widely accepted 
that if children’s health and well-being is to be promoted they should be involved in 
research, subject to special safeguards to protect their rights and interests.68
7.1  new Zealand guidelines for health research with children
Many different principles and guidelines have been developed for research with 
children. Those produced for the New Zealand context (although based on 
international standards) reinforce the notion that children should be included in 
research but that researchers should be aware of the rights of children,69 and there 
should be appropriate safeguards.68
‘Principles
1) Research involving children is important for the benefit of all children and 
should be supported, encouraged and conducted in an ethical manner.
2) Children are not small adults; they have their own unique set of interests.
3) Research should only be done with children if comparable research with adults 
could not answer the same question and the purpose of the research is to obtain 
knowledge relevant to the health needs of children.
4) A research procedure, which is not intended directly to benefit the child 
participant, is not necessarily unethical.
5) All proposals involving health research with children should be submitted to an 
ethics committee.
6) Legally valid consent should be obtained from the child, parent or guardian as 
appropriate. When parental consent is obtained, the assent or consent of the 
children should, wherever possible, also be obtained by the researcher.68
The ensuing guidelines published by these authors (and incorporated in the 
Operational Standard for Ethics Committees, updated edition, 2006) will be used in the 
next section of this report to highlight issues relating to the design and conducting 
of studies involving the testing of newborns for genetic susceptibility to T1D. The 
guidelines are included in full in the Appendix. 
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The authors highlight the importance of two issues that are crucial to research 
involving children: the degree of permissible risk to the child participant, and consent. 
These issues in particular will be discussed later in the context of the enrolment 
of children in research involving screening for genetic susceptibility to common 
multifactorial disorders. 
7.2  nature and design of research
The New Zealand guidelines for health research with children state that:
Before undertaking research with children, the investigator must ensure that:
i. children will not be involved in research that might equally well be carried out 
with adults
ii. the purpose of the research is to obtain knowledge relevant to the health needs 
of children
iii. if a choice of age groups is possible, older children should be involved in 
preference to younger ones
iv. the research is designed or supervised and carried out by people experienced in 
working with children
v. the number of children involved is limited to the number which is scientifically 
and clinically essential.68
As previously discussed there are now several large studies in progress that aim to 
elucidate the environmental triggers of T1D in genetically susceptible children. 
The most significant of these is the National Institutes of Health (NIH) -sponsored 
TEDDY study that has United States centres located in Colorado, Florida, Georgia, 
Pennsylvania and Washington as well as centres in Sweden, Finland and Germany. 
The aim is to follow up about 7000 genetically susceptible children from birth to 
fifteen years, which means that 40,000 newborns will be screened in Denver alone 
over a four-year period.24 It is highly likely that other multifactorial conditions will 
also be studied in this manner.
The TEDDY study, and others like it, have been extensively reviewed both by funding 
bodies and ethics committees and are presumably considered justifiable both 
scientifically and ethically. Important points that must have been considered during 
the review process, and that are relevant to the New Zealand guidelines concerning 
the nature and design of research, include:
• The serious nature of the disease being studied 
• The potential to gain knowledge concerning the pathogenesis of childhood T1D 
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• The potential for development of interventions to be used in the pre-diabetic 
phase
• The necessity of studying very young children due to the high likelihood that 
the environmental trigger(s) of T1D operate very early in life
• The paediatric experience of investigators.
Discussion in this paper has focused on T1D; it appears that there is some consensus 
that these large-scale studies are scientifically valid, and worthwhile. If children were 
not enrolled in such studies then we would be unable to understand the complex 
relationship between genetic susceptibility and environmental exposure in the 
pathogenesis of childhood T1D. While I concur with this position, I also consider 
that it is imperative that empirical research into ethical and psychosocial issues is 
incorporated into the longitudinal studies. It is equally as important to understand 
psychosocial reactions to testing as it is to unravel the pathogenesis of the disorder in 
question. In addition, the researching of psychosocial reactions provides a means of 
careful monitoring to detect adverse events during the course of research.
If therefore we can conclude that studies which involve screening newborns for 
T1D are scientifically justifiable, how can they best be designed to take into account 
the two crucial ethical issues in health research involving children that have been 
highlighted in the New Zealand principles and guidelines: minimisation of harm, 
and consent?68
7.  minimisation of harm
The New Zealand guidelines concerning the degree of potential harm permissible in 
research with children state that:
Research procedures or interventions which are not intended to be of direct benefit 
to the child participants, but which are likely to yield generalisable knowledge about 
the child’s disorder or condition which is of vital importance for the understanding 
or amelioration of the child’s disorder or condition, may be undertaken if:
i. any risk represents a minor increase over minimal risk
ii. the interventions or procedures present experiences to the child participants 
which are reasonably commensurate with those inherent in their actual or 
expected medical, psychological, social or educational situations.
Research procedures which are not intended to be of direct benefit to the child 
participants, and do not come within the scope of the above paragraph, may be 
undertaken only if the risk presented by the interventions to the child participant is:
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i. minimal
ii. commensurate with the importance of the knowledge to be gained.68
It is debatable which of these categories T1D screening research falls into. Of all the 
genetically susceptible children included in such a study, one in fifteen will develop 
T1D whereas the remainder will not. Who falls into which group is clearly unknown 
at the outset; so, ideally, all children should only be subjected to a minimal risk of 
harm from the research procedures. It is therefore important actively to attempt to 
minimise harm as far as possible in the design and running of these studies.
7.3.1  Minimisation of physical harm
Any clinical trial must include relevant safeguards to minimise adverse effects and 
protect participants from physical harm. These issues will not be discussed in detail 
here but of course hold true for longitudinal T1D studies and include:
• Minimisation of distress related to venepuncture by ensuring capabilities of 
staff and the use of local anaesthetic creams
• Ensuring that any physical examinations or other testing are conducted by staff 
experienced in dealing with children and in a child-friendly environment
• Monitoring parental behaviour that could impact upon the child (e.g. changes 
of milk formula) and providing appropriate advice.
7.3.2  Minimisation of psychological harm
Minimisation of potential psychosocial harm relating to parental knowledge of 
their newborn’s risk of T1D may be more difficult to achieve, but is potentially of 
considerable importance. Two major modifications to study design could ensure less 
psychosocial risk but both are problematic at a scientific or practical level.
1. Recruitment only of children from high-risk families 
In terms of minimising psychosocial risks, restricting genetic susceptibility testing to 
children in high-risk families (i.e. families with an affected first degree relative) makes 
sense. These children are known to have an increased risk: 3 to 6 per cent of relatives 
of T1D patients will develop the disease, compared to one in three hundred people 
in the general population.70 Children in these families are often rightly viewed as ‘at 
risk’ by their parents even if they do not undergo genetic testing.71 Given that baseline 
anxiety probably already exists within these families, genetic and immunologic testing 
may not induce anxiety. Instead it could confirm or dismiss the existing parental 
concerns, albeit only probabilistically.55
The practical advantage of selectively screening children from high-risk families is 
that a proportionately larger number of individuals ‘at risk’ will be identified with a 
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smaller sample. However the major disadvantage of recruiting only from high-risk 
families is that the total number identified may be too small for some research and 
the sample population may be biased.55 Only 10 per cent of childhood T1D occurs 
in children with an affected relative and the pathogenesis of T1D in affected families 
may be different to that in the general population,72 significantly reducing the value 
of the research. In addition, this strategy precludes assessment of psychosocial issues 
in the general population that must be considered well in advance of any proposal to 
screen more widely. 
2. General population research without disclosure of results
Another way to reduce psychosocial risk in genetic susceptibility research would 
be to design studies that do not require disclosure of individual results. This would 
eliminate the psychosocial harms of classifying an individual as ‘at risk’. However it 
would mean that all children would require follow-up auto-antibody screening which 
would be significantly more expensive and would subject many more children to the 
harm associated with venepuncture. Again, this strategy would preclude assessment 
of psychosocial issues. It is also quite possible that parents would not consent to 
genetic testing of their newborns under these conditions.55 
Concern regarding the practical and scientific implications of these two strategies, 
coupled with the underlying justifications for this type of research involving 
children, has led to the development of the large population-based studies. However, 
there remains the potential for psychosocial disturbance that could extend beyond 
the level of ‘minor harm’ proscribed in the guidelines concerning research with 
children.68 There is therefore a pressing need to investigate and monitor psychosocial 
reaction. This will provide important information when the introduction of clinical 
testing is considered. In addition, if it appears that individual parents are particularly 
distressed during the course of a study, strategies for attempting to minimise harm 
should be in place. 
General recommendations regarding such psychosocial monitoring and research 
include the stipulations that:
• It should form an integral part of the design of studies into the pathogenesis of 
multifactorial disorders in childhood
• Psychological assessment questionnaires remain useful tools and should 
continue to be used in different populations and for longer durations than 
already described. Clinical cut-off scores are available for most of these 
assessments and parents scoring above these levels should be referred to the 
appropriate services (with their agreement)
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• Qualitative research, including interviews and focus groups, would be useful 
in developing a more detailed understanding of how parents react to newborn 
genetic susceptibility testing. Parents may provide important information 
concerning how useful they found aspects of information provision and other 
elements of study design
• If studies are likely to be prolonged, children should be directly included in 
psychosocial research. This could include assessment of childhood behaviour, 
and eliciting the views of children on the research and, later, on genetic 
susceptibility testing and its implications. 
7.  consent 
The New Zealand guidelines for health research with children state:
If the child is below the age of 16, and lacks the necessary competence to give 
legally effective consent:
(a) the child’s parent or legal guardian must give permission for the child’s  
 participation
(b) the child’s assent must be obtained unless the child is unable to   
 communicate.68
Any research in the newborn period clearly necessitates the use of proxy consent, and 
the newborn is unable even to provide assent. One aspect of study design may have 
significant impact upon rates of parental consent for this type of research: whether 
the existing newborn screening infrastructure is used, or whether an entirely separate 
process is employed.
The benefits of using samples routinely taken for newborn screening (‘the Guthrie 
card’: at about day two to five) is that almost all babies undergo this important 
routine testing aimed at detecting metabolic and endocrine disorders that require 
immediate treatment. This allows potential for high participation rates that would 
aid the progress of the research. The risk is that parents may conflate experimental 
and standard screening and consent to both without understanding that the former 
is non-therapeutic.55 This could leave them unprepared for a positive test result, and 
undermine their autonomy. An alternative, but serious, risk is that parents could 
mistakenly decide that all newborn screening is experimental and refuse both 
standard and diabetes screening, despite the proven medical benefit of the former.12
The potential for any decline in public confidence in or uptake rates for standard 
newborn screening programmes should be very carefully considered when designing 
studies into the pathogenesis of multifactorial disorders such as T1D. I recommend 
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that all aspects of research protocol, including the acquisition of blood samples, 
should be entirely separated from standard newborn screening. 
7.4.1  Proxy consent
The New Zealand guidelines for research involving children clearly state that 
investigators must ensure that: 
… children, and where appropriate their caregivers, have been fully informed about 
the research in a manner best suited to their needs.68 
If proxy consent is required
… the proxy must also be given full information about the research and advised 
of the child’s right to decline participation or withdraw at any time. The proxy 
must be given an opportunity to ask questions and have them answered to their 
satisfaction.68
In relation to newborn T1D screening research it seems reasonable to suggest that, at 
a minimum, the following should be included in information given to parents:
• The aims of the research
• The meaning of a positive genetic susceptibility test
• The benefits of the research. These are likely to relate to improved knowledge 
concerning the pathogenesis of T1D in general rather than any specific benefit 
to their child
• Potential physical risks
• Potential psychological risks and the current uncertainty surrounding the 
magnitude and importance of these
• Potential implications for insurance.
The New Zealand guidelines go on to state that:
Before undertaking research with children, the investigator must ensure that 
appropriate consent is sought on the basis of the information provided.68
In the case of T1D screening, research consent should be sought from the parent or 
guardian but consideration should still be given to the implications this may have for 
the future autonomy of the child.
7.4.2  Future autonomy of the child
Despite its widespread use, there are some fairly obvious inherent ambiguities in the 
concept of proxy consent, in that consent generally expresses something of oneself. 
In other words, a person who consents does so on the basis of their own unique 
1
personal beliefs and values;73 but this cannot be the case for newborn screening as it 
is not possible to gauge accurately what a child’s future beliefs will be. While it is clear 
that a practical solution to the newborn’s incapacity to consent is required, and it also 
seems reasonable to suggest that the most appropriate approach is parental proxy 
consent, we need to be mindful of this significant theoretical difference between 
proxy and individual informed consent. 
It has been argued that predictive genetic testing in childhood breaches a child’s 
future autonomy by removing the right to decide about testing as an autonomous 
adolescent or adult.74 Alternative views suggest that genetic knowledge may in fact 
promote autonomy by enhancing the child’s concept of self and self-knowledge, 
which in turn is useful for forming one’s conception of the good life for oneself.75 
Determining the relative merits of these arguments is even more complex when 
considering probabilistic testing such as that described here. These issues are 
discussed in more detail in the section of the report by Deborah Lawson entitled 
‘Genetic Testing of Children Who Cannot Give a Valid Consent’.
At the outset of newborn T1D studies it is clear that proxy consent will be required. 
However, some of these studies, such as the international TEDDY consortium study, 
aim to follow up children for fifteen years. This means that at some stage during the 
study period it will become necessary for children to be informed about the nature of 
the research, and either give their assent or decline further involvement. 
7.4.3  Information for children
When children and young people participate in research, age and maturity determine 
their specific needs for information provision. In order to empower children and 
young people as research participants, researchers must provide information at a 
comprehension level and in a medium that is age appropriate. The exact age at which 
to begin involving young people remains at the discretion of researchers and the ethics 
committees that monitor their research. However, with the use of developmentally 
appropriate information, most children as young as five years of age can understand 
what research is about and are capable of giving voluntary assent.76
Researchers must tailor information to the needs of the children and young people 
they approach, not only in relation to the content of the information they provide 
and the developmental stage for which it is intended, but also the way in which 
it is presented. This may include simplifying the information, including more 
comparisons, analogies or examples or using pictures and diagrams, or video format, 
to increase the probability of an informed decision.76 
In ongoing, prolonged studies it is likely (and preferable) that parents and researchers 
will impart knowledge on a gradual, incremental basis as the child’s level of 
understanding permits. It should be noted that conveying information concerning 
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genetic risk to competent adults can be difficult, and is dependent upon a complex array 
of individual characteristics.58 It is likely that a range of difficulties and requirements 
for counselling will arise for children enrolled in such research. At present there is little 
guidance available regarding the best methods of imparting such information (given 
the generally prohibitive testing guidelines). Studies currently in progress would be 
well advised to include within their data collection protocols information on when and 
how children were informed about the study and genetic test result, and the effects this 
had upon the child. This information will be required not only in the context of future 
research but also if testing becomes part of clinical practice.
7.4.4  Child assent and consent or refusal
The New Zealand guidelines for health research involving children state:
Care must be taken to ensure that no pressure is placed upon a child to consent to 
participate in research, especially if the procedures are not intended to be of direct 
benefit to the child participants.68
Once research procedures have been adequately explained to children their assent, 
consent or refusal must be respected. 
Assent should not be equated with consent. The purpose of assent is not to treat 
children as if they are capable of making decisions that are as fully informed and 
autonomous as those made by adults. Rather it is important because it reminds us 
that children should be treated with dignity and respect and because permitting 
children a shared role in decision-making benefits their development as autonomous 
individuals.77
Many children enjoy, and benefit from, participating in research. Feeling good 
about helping others is one of the most commonly quoted positive effects.78 There is 
very little empirical data concerning children’s participation in genetic research, in 
particular; but, in studies relating to the Swedish alpha1AT screening programme, 
adolescents who had been screened at birth retrospectively recommended neonatal 
screening to others.79
In summary, studies involving screening for genetic susceptibility to T1D are justified 
on the basis of the potential for significant health benefits for children. However, 
there is potential for harmful effects within these research protocols and efforts 
must be made to minimise these. In particular this means that psychosocial effects 
must be further investigated and monitored. The issue of consent to testing is also 
complex and researchers will need to adapt to the evolving requirements regarding 
information, and capacity for assent, of their child participants.
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  conclusions anD imPlications
Many challenges have been identified since the completion of the Human Genome 
Project, with one of the most significant, perhaps, being how genetic susceptibility 
testing (or genomic profiling) might be integrated into medical practices, such as 
newborn screening. 
This report has briefly discussed scientific or practical matters such as analytic 
validity, clinical validity and utility. These important issues can only be adequately 
addressed with high quality biomedical research including longitudinal population 
cohort studies designed to identify genetic and environmental contributors to 
health and to assess the effect of individual gene variants on disease risk.33 In the 
case of T1D these studies are underway.80 As they proceed, interventions designed to 
prevent disease onset may become available and will also require careful testing in 
longitudinal intervention studies.
The review of psychosocial effects of newborn genetic susceptibility testing has 
highlighted the fact that there are several good reasons to be concerned about such 
testing. These include features of the newborn period, features of the tests themselves 
and evidence from previous and current newborn screening programmes. There 
remains a relative paucity of empirical research in this area but evidence, including 
the results of my own research, is gradually accruing to suggest that families generally 
cope well with T1D genetic risk information concerning their children, if it is conveyed 
sensitively.59–61,62 At this stage, the research remains fairly limited both in focus and 
duration and the need for further research in this area has been highlighted.
Achieving a proper balance between the social good, that may come from performing 
this type of research involving children, and the level of protection offered to child 
participants is a significant challenge.77 Such research itself involves complex ethical 
and social issues and these have been discussed and recommendations made for 
aspects of study design. Particular attention must be paid to minimising risks to 
children and implementing procedures for obtaining the informed consent or assent 
of parents and child participants. 
I have argued that empirical research concerning potential psychosocial harms 
of newborn susceptibility testing is essential if we are to make rational decisions 
regarding the use of such tests. Analysis of harms and benefits is fundamental to 
considering the introduction of new screening programmes. However, there are many 
other important ethical and social issues that will also require consideration prior to 
the introduction of any screening programme. These include further consideration 
of consent for testing (see the section by Deborah Lawson entitled ‘Genetic Testing 
of Children Who Cannot Give a Valid Consent’); data storage and confidentiality 
(see sections ‘Legal Issues Relating to Newborn Screening’ by Kirsty Dobbs and 
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Richman Wee and ‘Researching Human Genetic Variation’ by Dana Wensley); and 
the potential for discrimination (discussed in relation to race and ethnicity in the 
section ‘Researching Human Genetic Variation’ by Dana Wensley).
Newborn screening for genetic susceptibility is currently only applicable in research 
settings because of the lack of detailed knowledge concerning harms and benefits; the 
lack of a preventative measure; and the relative expense and complexity of testing. 
The research alluded to here aims to provide more information on which to base 
decisions about future uses for tests. If the pathogenesis of T1D is eventually better 
understood, and a preventative measure developed (even if only partially effective), 
then the benefits of screening may well outweigh the risks. If this eventuates, screening 
for genetic susceptibility to T1D should be reassessed using the usual processes and 
screening criteria applied when considering the introduction of a new test onto 
standard newborn screening panels.81 
aPPenDix
These guidelines are incorporated in the Operational Standard for Ethics Committees, 
updated edition, 2006
ethical guidelines for health research with children
Nature and design of research
1. Before undertaking research with children, the investigator must ensure that:
 i. children will not be involved in research that might equally well be carried  
 out with adults
 ii. the purpose of the research is to obtain knowledge relevant to the health   
 needs of children
 iii. if a choice of age groups is possible, older children should be involved in   
 preference to younger ones
 iv. the research is designed or supervised and carried out by people experienced  
 in working with children
 v. the number of children involved is limited to the number which is   
 scientifically and clinically essential.
Risk
2. Research procedures or interventions which are intended to provide direct 
therapeutic benefit to the child participants may be undertaken if:
 i. the risk is justified by the anticipated benefit to the child participants
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 ii. any relation of the anticipated benefit to the risk is likely to be at least as   
 favourable to the child participant as any available alternative.
3. Research procedures or interventions which are not intended to be of direct 
benefit to the child participants, but which are likely to yield generalisable 
knowledge about the child’s disorder or condition which is of vital importance 
for the understanding or amelioration of the child’s disorder or condition, may 
be undertaken if:
 i. any risk represents a minor increase over minimal risk
 ii. the interventions or procedures present experiences to the child participants  
 which are reasonably commensurate with those inherent in their actual or  
 expected medical, psychological, social or educational situations.
4. Research procedures which are not intended to be of direct benefit to the 
child participants, and do not come within the scope of 2 or 3 above, may 
be undertaken only if the risk presented by the interventions to the child 
participant is:
 i. minimal
 ii. commensurate with the importance of the knowledge to be gained.
informed consent
Information
5. When inviting children to participate in any research, the investigator must 
ensure that the children, and, where appropriate, the children’s parents, 
guardians or caregivers, have been fully informed about the research in a 
manner best suited to their needs.
 i. Each child must be given full information about the research in a form that  
 he or she can readily understand.
 ii. Children must be advised of their right to decline participation and their   
 right to withdraw from the research at any time without giving a reason.
 iii. Investigators must give the children an opportunity to ask questions and to  
 have those questions answered to the children’s satisfaction.
 iv. If proxy consent is required, the proxy must also be given full information  
 about the research and be advised of the child’s right to decline participation  
 or withdraw from the research at any time.
 v. The proxy must be given an opportunity to ask questions and have them   
 answered to the proxy’s satisfaction.
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Consent
6. Before undertaking research with children, the investigator must ensure that 
appropriate consent is sought on the basis of the information provided.
 i. The consent of a child of or over the age of 16 must be obtained and has   
 the same effect as if the child were of full age.
 ii. If the child is below the age of 16, but has the competence to understand the  
 nature, risks and consequences of the research:
  (a) the consent of the child must be obtained; and
  (b) that consent will have the same effect as if the child were of full age.
 iii. If the child is below the age of 16, and lacks the necessary competence to give 
 legally effective consent:
  (a) the child’s parent or legal guardian must give permission for the child’s  
  participation
  (b) the child’s assent must be obtained unless the child is unable to   
  communicate
  (c) the refusal of a child to participate in research must be respected   
  unless:
   •   according to the research protocol the child would receive therapy  
   for which there is no medically acceptable alternative; or
   • the research comes within the scope of category 3 above.
 iv. Care must be taken to ensure that no pressure is placed upon a child to   
 consent to participate in research, especially if the procedures are not   
 intended to be of direct benefit to the child participants (as in categories 3  
 and 4 above).
 v. The requirement for written consent should take into consideration the age  
 and competence of the child.
Inducements
7. Families and children must not receive any financial payments or other  
reward for participating in the research. Only expenses resulting from 
participation may be reimbursed.
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9.2.4  Health research data
8. Retention and use of personally identifiable health research data:
 i. Research data pertaining to the child participants should be retained   
 by the researcher for ten years after the child has attained the age of 16.
 ii. Children have the right to withdraw consent to the continued use or   
 retention of personally identifiable health research data once they attain the  
 age of 16.
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